Jefferies downgrades Kezer Life Sciences stock on FDA setback
NegativeFinancial Markets

Jefferies has downgraded the stock of Kezer Life Sciences following a setback with the FDA, which is a significant blow for the company. This downgrade reflects concerns about the company's future prospects and could impact investor confidence. Such regulatory hurdles can delay product launches and affect market performance, making it crucial for Kezer to address these challenges swiftly.
— Curated by the World Pulse Now AI Editorial System